Otto Visser

32.9k total citations · 5 hit papers
256 papers, 12.4k citations indexed

About

Otto Visser is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Otto Visser has authored 256 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 59 papers in Pathology and Forensic Medicine and 46 papers in Epidemiology. Recurrent topics in Otto Visser's work include Lymphoma Diagnosis and Treatment (51 papers), Global Cancer Incidence and Screening (49 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Otto Visser is often cited by papers focused on Lymphoma Diagnosis and Treatment (51 papers), Global Cancer Incidence and Screening (49 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Otto Visser collaborates with scholars based in Netherlands, United States and Italy. Otto Visser's co-authors include Babs G. Taal, J.W.W. Coebergh, Anna Gavin, Manola Bettio, Giorgia Randi, Freddie Bray, Isabelle Soerjomataram, Murielle Colombet, T Dyba and Jacques Ferlay and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Otto Visser

243 papers receiving 12.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

2018 1.7k citations Jacques Ferlay, Murielle Colombet et al. European Journal of Cancer profile →
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study

2013 1.4k citations Otto Visser, Sabine Siesling et al. profile →
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

2010 665 citations Otto Visser et al. Blood profile →
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project

2014 373 citations Otto Visser et al. Cancer Epidemiology profile →
Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands

2018 225 citations Otto Visser, Flora E. van Leeuwen et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Otto Visser

Since Specialization

Citations

This map shows the geographic impact of Otto Visser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Otto Visser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Otto Visser more than expected).

Fields of papers citing papers by Otto Visser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Otto Visser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Otto Visser. The network helps show where Otto Visser may publish in the future.

Co-authorship network of co-authors of Otto Visser

This figure shows the co-authorship network connecting the top 25 collaborators of Otto Visser. A scholar is included among the top collaborators of Otto Visser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Otto Visser. Otto Visser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased incidence, survival, and registration quality of primary hepato‐pancreato‐biliary cancers in the Netherlands Cancer Registry 2025 ·International Journal of Cancer ·Lydia G. van der Geest, Marianne van der Mark, Joanne Verheij, Arantza Fariña Sarasqueta, Judith de Vos‐Geelen, Marc G. Besselink, Vincent E. de Meijer, Ignace H. J. T. de Hingh, Bert A. Bonsing, Philip R. de Reuver, François E.J.A. Willemssen, Pauline A. J. Vissers, Otto Visser, (unknown)	0
2	The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering 2025 ·British Journal of Haematology ·(unknown), (unknown), Tanja Netelenbos, Marina Kartachova, Roger E. G. Schutgens, Otto Visser, Peter E. Westerweel, Jaap Jan Zwaginga, (unknown), Rick Kapur, Masja de Haas, Leendert Porcelijn, Martin R. Schipperus	0
3	Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry 2025 ·Cancer Epidemiology ·Marissa C. van Maaren, Quirinus J.M. Voorham, (unknown), Linda de Munck, Jelle Wesseling, Otto Visser, Sabine Siesling	1
4	Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity 2024 ·Supportive Care in Cancer ·Nick de Jonge, Jeroen J. W. M. Janssen, Paula F. Ypma, A H E Herbers, (unknown), (unknown), Jody M.W. van den Ouweland, Aart Beeker, Otto Visser, Sonja Zweegman, Nicole M. A. Blijlevens, Michiel A. van Agtmael, Jonne J. Sikkens	2
5	Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019 2023 ·EClinicalMedicine ·(unknown), David van Klaveren, Otto Visser, Matthias A.W. Merkx, Hester F. Lingsma, V.E.P.P. Lemmens, Avinash G. Dinmohamed	1
6	Quality indicators: completeness, validity and timeliness of cancer registry data contributing to the European Cancer Information System 2023 ·Frontiers in Oncology ·Francesco Giusti, Carmen Martos, R. Carvalho, Liesbet Van Eycken, Otto Visser, Manola Bettio	13
7	ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning 2023 ·British Journal of Haematology ·(unknown), David C. de Leeuw, Caroline E. Rutten, Otto Visser, Man Tang, (unknown), (unknown), Bart J. Biemond, Arjan A. van de Loosdrecht, Mette D. Hazenberg, Ellen Meijer, Erfan Nur	2
8	Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands 2023 ·Haematologica ·(unknown), Mirian Brink, Wouter J. Plattel, Marjolein van der Poel, Marie José Kersten, Mariëlle J. Wondergem, Lara H. Böhmer, Feng Jung Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Karen J. Neelis, Anne P.G. Crijns, Laurien Daniëls, (unknown), Joost S.P. Vermaat, Gerwin Huls, Marcel Nijland	5
9	Changes in survival in de novo metastatic cancer in an era of new medicines 2023 ·JNCI Journal of the National Cancer Institute ·Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G.E. de Vries, Carin A. Uyl‐de Groot, Sabine Siesling	22
10	Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands 2021 ·Leukemia ·(unknown), Otto Visser, Eduardus F. M. Posthuma, Peter E. Westerweel, Jeroen J. W. M. Janssen, Nicole M. A. Blijlevens, Avinash G. Dinmohamed	2
11	The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018 2021 ·British Journal of Haematology ·(unknown), David van Klaveren, (unknown), Eduardus F. M. Posthuma, Otto Visser, Peter E. Westerweel, Jeroen J. W. M. Janssen, Nicole M. A. Blijlevens, Avinash G. Dinmohamed	14
12	Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017 2020 ·Leukemia ·(unknown), Otto Visser, Peter E. Westerweel, Jeroen J. W. M. Janssen, Nicole M. A. Blijlevens, Avinash G. Dinmohamed	5
13	Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 breakdown → 2018 ·European Journal of Cancer ·Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram, T Dyba, Giorgia Randi, Manola Bettio, Anna Gavin, Otto Visser, Freddie Bray	1716
14	Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe 2017 ·European Journal Of Haematology ·(unknown), Noortje Thielen, Jeroen J. W. M. Janssen, Mels Hoogendoorn, (unknown), Peter J.M. Valk, Otto Visser, Jan J. Cornelissen, Peter E. Westerweel	3
15	A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma 2015 ·Clinical Cancer Research ·(unknown), Johannes Berkhof, (unknown), Michal Sieniawski, (unknown), Wieke H.M. Verbeek, Otto Visser, Joost J. Oudejans, Chris J.L.M. Meijer, Chris J. Mulder, Anne Lennard, Saskia A.G.M. Cillessen	18
16	Caphosol in prevention of oral mucositis in autologous stem cell transplant recipients after high-dose melphalan (CASH) 2012 ·Bone Marrow Transplantation ·(unknown), Carin Potting, Walter J. F. M. van der Velden, Koen Theunissen, Johan Maertens, Marinus van Marwijk Kooy, Harry C. Schouten, Otto Visser, E. Willems, Anne Sonet, Nicole Blijlevens	2
17	Volwassen kankerpatiënten overleven langer in Nederland 5-jaarsoverleving 12% toegenomen tussen 1989-1993 en 2004-2008 2011 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Sabine Siesling, Otto Visser, (unknown), Henrike E. Karim‐Kos, Lonneke V. van de Poll‐Franse, Katja K.H. Aben, Ronald Damhuis	2
18	Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis 2010 ·Journal of Clinical Oncology ·David A. Palma, Otto Visser, Frank J. Lagerwaard, J. Belderbos, Ben J. Slotman, Suresh Senan	347
19	Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells 2006 ·Blood ·Abdulbaqi Al–Toma, Otto Visser, (unknown), B. Mary E. von Blomberg, Wieke H.M. Verbeek, Petra E.T. Scholten, Gert J. Ossenkoppele, Peter C. Huijgens, Chris J. Mulder	137
20	Incidentie van baarmoederhalskanker naar geboorteland bij vrouwen in Noord-Holland in 1988-1998 [Incidence of cervical cancer in women in North-Holland by country of birth from 1988-1998]: 2003 ·TNO Repository ·Otto Visser, (unknown), Flora E. van Leeuwen, Neil K. Aaronson, Ferko Öry	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact